MA40364A - Polythérapie pour le traitement du cancer - Google Patents
Polythérapie pour le traitement du cancerInfo
- Publication number
- MA40364A MA40364A MA040364A MA40364A MA40364A MA 40364 A MA40364 A MA 40364A MA 040364 A MA040364 A MA 040364A MA 40364 A MA40364 A MA 40364A MA 40364 A MA40364 A MA 40364A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- treatment
- combination therapy
- combination
- staggered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des procédés comprenant la polythérapie pour le traitement du cancer. Elle concerne également des inhibiteurs de la voie wnt en combinaison avec des inhibiteurs mitotiques administrés de manière échelonnée ou selon un dosage séquentiel pour le traitement du cancer et d'autres maladies.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462042710P | 2014-08-27 | 2014-08-27 | |
US201462086376P | 2014-12-02 | 2014-12-02 | |
US201562134661P | 2015-03-18 | 2015-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40364A true MA40364A (fr) | 2016-03-03 |
Family
ID=55400550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040364A MA40364A (fr) | 2014-08-27 | 2015-08-27 | Polythérapie pour le traitement du cancer |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170247465A1 (fr) |
EP (1) | EP3185884A4 (fr) |
JP (1) | JP2017526676A (fr) |
CN (1) | CN106714822A (fr) |
AU (1) | AU2015308854A1 (fr) |
CA (1) | CA2959529A1 (fr) |
MA (1) | MA40364A (fr) |
MX (1) | MX2017002364A (fr) |
WO (1) | WO2016033284A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
JP6951973B2 (ja) | 2014-11-12 | 2021-10-20 | シージェン インコーポレイテッド | グリカン相互作用化合物及び使用方法 |
US20180244783A1 (en) * | 2015-08-31 | 2018-08-30 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
WO2017083582A1 (fr) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Composés interagissant avec le glycane et méthodes d'utilisation |
WO2018094143A1 (fr) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Composés interagissant avec le glycane et méthodes d'utilisation |
AU2018226824A1 (en) * | 2017-03-03 | 2019-09-19 | Seagen Inc. | Glycan-interacting compounds and methods of use |
WO2019124603A1 (fr) * | 2017-12-22 | 2019-06-27 | 경상대학교병원 | Composition destinée à prévenir ou à traiter une chéloïde contenant iwr-1 à titre de principe actif |
JP7369968B2 (ja) * | 2017-12-27 | 2023-10-27 | 公益財団法人がん研究会 | 抗がん剤 |
EP3784240B1 (fr) * | 2018-04-24 | 2023-09-20 | Universidade do Minho | Wnt6 comme biomarqueur oncogènique du glioblastome, et utilisations d'inhibiteurs associés pour traiter le glioblastome surexprimant wnt6 |
CN113648425B (zh) * | 2021-08-18 | 2022-05-03 | 中国人民解放军军事科学院军事医学研究院 | Plk1抑制剂和csnk1d/e抑制剂对肿瘤细胞具有协同抑制作用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010037041A2 (fr) * | 2008-09-26 | 2010-04-01 | Oncomed Pharmaceuticals, Inc. | Agents se liant aux récepteurs frizzled et leurs utilisations |
CA2794674A1 (fr) * | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Agents de liaison aux recepteurs frizzled et leurs utilisations |
WO2014066328A1 (fr) * | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Méthodes de traitement de tumeurs neuro-endocrines à l'aide d'agents liants de parcours wnt |
JP2016510411A (ja) * | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
-
2015
- 2015-08-27 US US15/506,424 patent/US20170247465A1/en not_active Abandoned
- 2015-08-27 MA MA040364A patent/MA40364A/fr unknown
- 2015-08-27 WO PCT/US2015/047102 patent/WO2016033284A1/fr active Application Filing
- 2015-08-27 AU AU2015308854A patent/AU2015308854A1/en not_active Abandoned
- 2015-08-27 MX MX2017002364A patent/MX2017002364A/es unknown
- 2015-08-27 CA CA2959529A patent/CA2959529A1/fr not_active Abandoned
- 2015-08-27 EP EP15836791.2A patent/EP3185884A4/fr not_active Withdrawn
- 2015-08-27 JP JP2017511221A patent/JP2017526676A/ja active Pending
- 2015-08-27 CN CN201580046087.9A patent/CN106714822A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2017002364A (es) | 2017-05-17 |
JP2017526676A (ja) | 2017-09-14 |
WO2016033284A4 (fr) | 2016-04-28 |
CA2959529A1 (fr) | 2016-03-03 |
WO2016033284A1 (fr) | 2016-03-03 |
AU2015308854A1 (en) | 2017-03-02 |
EP3185884A1 (fr) | 2017-07-05 |
EP3185884A4 (fr) | 2018-04-11 |
CN106714822A (zh) | 2017-05-24 |
US20170247465A1 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40364A (fr) | Polythérapie pour le traitement du cancer | |
IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
IL250172A0 (en) | Medical methods and combinations for the treatment of tumors | |
PH12017500601A1 (en) | Anti-tnf compounds | |
PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
PL3242947T3 (pl) | Terapia genowa i elektroporacja do leczenia zmian złośliwych | |
HK1252813A1 (zh) | 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物 | |
MX2017002489A (es) | Agentes terapeuticos humanos. | |
IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
MX2017015311A (es) | Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. | |
IL277238A (en) | Modified oligonucleotides for use in the treatment of tauopathy | |
EP3156054A4 (fr) | Médicament pour la prévention et/ou le traitement de maladies induites par le stress | |
IL248328A0 (en) | Bracelets for the administration of drugs for the treatment of resistant cancer and for the use of combined therapy | |
HK1258235A1 (zh) | 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑 | |
IL245861A0 (en) | Use of substances to treat drug-resistant tumors | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
GB201416605D0 (en) | Combination therapy to reduce the risk of and to treat cancer |